Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

Inclusion Criteria

• •Men or women 18-65 years of age at time of consent
• •Chronic plaque-type psoriasis diagnosed for at least 6 months at time of randomization
• •At randomization, moderate to severe psoriasis as defined by:
• •PASI score of 12 or greater and,
• •IGA score of 3 or greater and,
• •Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater.
• •Female patients may be included according to the following:
• •Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, using highly effective methods of contraception during dosing and for 5 times the terminal half-life of study treatment.
• •Male subjects must agree to comply with two highly effective contraceptive methods